New Research: Key Drivers of Growth for Voya Financial, Conduent, Milacron, Altair Engineering, Genesis Healthcare, and Protalix BioTherapeutics — Factors of Influence, Major Initiatives and Sustained Production

Author's Avatar
Jan 29, 2019
Article's Main Image

NEW YORK, Jan. 29, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Voya Financial, Inc. (:VOYA), Conduent Inc. (:CNDT), Milacron Holdings Corp. (:MCRN), Altair Engineering Inc. (ALTR, Financial), Genesis Healthcare, Inc. (:GEN), and Protalix BioTherapeutics, Inc. (:PLX), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.

Complimentary Access: Research Reports

Full copies of recently published reports are available to readers at the links below.

VOYA DOWNLOAD: http://MarketSourceResearch.com/register/?so=VOYA
CNDT DOWNLOAD: http://MarketSourceResearch.com/register/?so=CNDT
MCRN DOWNLOAD: http://MarketSourceResearch.com/register/?so=MCRN
ALTR DOWNLOAD: http://MarketSourceResearch.com/register/?so=ALTR
GEN DOWNLOAD: http://MarketSourceResearch.com/register/?so=GEN
PLX DOWNLOAD: http://MarketSourceResearch.com/register/?so=PLX

(You may have to copy and paste the link into your browser and hit the [ENTER] key)

The new research reports from Market Source Research, available for free download at the links above, examine Voya Financial, Inc. (:VOYA), Conduent Inc. (:CNDT), Milacron Holdings Corp. (:MCRN), Altair Engineering Inc. (ALTR, Financial), Genesis Healthcare, Inc. (:GEN), and Protalix BioTherapeutics, Inc. (:PLX) on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today's readers below.

-----------------------------------------

Important Notice: the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. All information in this release was accessed January 25th, 2019. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.

-----------------------------------------

VOYA FINANCIAL, INC. (VOYA, Financial) REPORT OVERVIEW

Voya Financial's Recent Financial Performance

For the three months ended September 30th, 2018 vs September 30th, 2017, Voya Financial reported revenue of $2,252.00MM vs $2,184.00MM (up 3.11%) and analysts estimated basic earnings per share $0.89 vs $0.83 (up 7.23%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, Voya Financial reported revenue of $8,618.00MM vs $8,788.00MM (down 1.93%) and analysts estimated basic earnings per share -$16.25 vs -$1.63. Analysts expect earnings to be released on February 5th, 2019. The report will be for the fiscal period ending December 31st, 2018. The reported EPS for the same quarter last year was $0.87. The estimated EPS forecast for the next fiscal year is $5.26 and is expected to report on February 5th, 2019.

To read the full Voya Financial, Inc. (VOYA, Financial) report, download it here: http://MarketSourceResearch.com/register/?so=VOYA

-----------------------------------------

CONDUENT INC. (CNDT, Financial) REPORT OVERVIEW

Conduent's Recent Financial Performance

For the three months ended September 30th, 2018 vs September 30th, 2017, Conduent reported revenue of $1,304.00MM vs $1,480.00MM (down 11.89%) and analysts estimated basic earnings per share -$1.16 vs -$0.09. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Conduent reported revenue of $6,022.00MM vs $6,408.00MM (down 6.02%) and analysts estimated basic earnings per share $0.84 vs -$4.85. Analysts expect earnings to be released on February 20th, 2019. The report will be for the fiscal period ending December 31st, 2018. Reported EPS for the same quarter last year was $0.31. The estimated EPS forecast for the next fiscal year is $1.12 and is expected to report on February 20th, 2019.

To read the full Conduent Inc. (CNDT, Financial) report, download it here: http://MarketSourceResearch.com/register/?so=CNDT

-----------------------------------------

MILACRON HOLDINGS CORP. (MCRN, Financial) REPORT OVERVIEW

Milacron's Recent Financial Performance

For the three months ended September 30th, 2018 vs September 30th, 2017, Milacron reported revenue of $308.30MM vs $314.70MM (down 2.03%) and analysts estimated basic earnings per share $0.21 vs $0.18 (up 16.67%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, Milacron reported revenue of $1,234.20MM vs $1,166.70MM (up 5.79%) and analysts estimated basic earnings per share $0.02 vs $0.45 (down 95.56%). Analysts expect earnings to be released on February 19th, 2019. The report will be for the fiscal period ending December 31st, 2018. Reported EPS for the same quarter last year was $0.47. The estimated EPS forecast for the next fiscal year is $1.92 and is expected to report on February 19th, 2019.

To read the full Milacron Holdings Corp. (MCRN, Financial) report, download it here: http://MarketSourceResearch.com/register/?so=MCRN

-----------------------------------------

ALTAIR ENGINEERING INC. (ALTR, Financial) REPORT OVERVIEW

Altair Engineering's Recent Financial Performance

For the three months ended September 30th, 2018 vs September 30th, 2017, Altair Engineering reported revenue of $93.87MM vs $84.94MM (up 10.52%) and basic earnings per share $0.10 vs -$0.59. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Altair Engineering reported revenue of $333.33MM vs $313.24MM (up 6.41%) and analysts estimated basic earnings per share -$1.89 vs $0.21. Analysts expect earnings to be released on March 20th, 2019. The report will be for the fiscal period ending December 31st, 2018. The reported EPS for the same quarter last year was $0.04. The estimated EPS forecast for the next fiscal year is $0.54 and is expected to report on March 20th, 2019.

To read the full Altair Engineering Inc. (ALTR, Financial) report, download it here: http://MarketSourceResearch.com/register/?so=ALTR

-----------------------------------------

GENESIS HEALTHCARE, INC. (GEN, Financial) REPORT OVERVIEW

Genesis Healthcare's Recent Financial Performance

For the three months ended September 30th, 2018 vs September 30th, 2017, Genesis Healthcare reported revenue of $1,217.27MM vs $1,315.45MM (down 7.46%) and analysts estimated basic earnings per share -$0.57 vs -$3.94. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Genesis Healthcare reported revenue of $5,373.74MM vs $5,732.43MM (down 6.26%) and analysts estimated basic earnings per share -$6.15 vs -$0.71. Analysts expect earnings to be released on March 15th, 2019. The report will be for the fiscal period ending December 31st, 2018. The reported EPS for the same quarter last year was -$0.36. The estimated EPS forecast for the next fiscal year is -$1.02 and is expected to report on March 15th, 2019.

To read the full Genesis Healthcare, Inc. (GEN, Financial) report, download it here: http://MarketSourceResearch.com/register/?so=GEN

-----------------------------------------

PROTALIX BIOTHERAPEUTICS, INC. (PLX) REPORT OVERVIEW

Protalix BioTherapeutics' Recent Financial Performance

For the three months ended September 30th, 2018 vs September 30th, 2017, Protalix BioTherapeutics reported revenue of $0.66MM vs $7.53MM (down 91.19%) and analysts estimated basic earnings per share -$0.10 vs -$0.09. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Protalix BioTherapeutics reported revenue of $19.24MM vs $9.20MM (up 109.17%) and analysts estimated basic earnings per share -$0.65 vs -$0.29. Analysts expect earnings to be released on March 5th, 2019. The report will be for the fiscal period ending December 31st, 2018. The reported EPS for the same quarter last year was -$0.10. The estimated EPS forecast for the next fiscal year is -$0.06 and is expected to report on March 5th, 2019.

To read the full Protalix BioTherapeutics, Inc. (PLX) report, download it here: http://MarketSourceResearch.com/register/?so=PLX

-----------------------------------------

ABOUT MARKET SOURCE RESEARCH

Market Source Research delivers the key research reports that helps serious investors, registered brokers, professional traders, and personal investment advisers find reliable information in today's markets. Market Source Research's team is comprised of financial professionals, many of which hold Chartered Financial Analyst® (CFA®) designations and FINRA® BrokerCheck® certifications. Whether identifying emerging trends, or discovering new opportunity, the team at Market Source Research is dedicated to providing accurate, informative, and objective content that's ahead of the curve. With insights on individual companies as well as sectors, readers get the industry's best available combination of big-picture perspective as well as granular detail.

REGISTERED MEMBER STATUS

Market Source Research's oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered Members") working within Equity Research, Media, and Compliance departments. Market Source Research's roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Market Source Research have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Market Source Research's Compliance department by Phone, at +1 (704) 343-6361, or by E-mail at [email protected].

LEGAL NOTICES

Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Market Source Research, Market Source Research members, and/or Market Source Research affiliates are not responsible for any gains or losses that result from the opinions expressed. Market Source Research makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Market Source Research has not been compensated for the publication of this press release by any of the above mentioned companies. Market Source Research is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.

Media Contact:
Hugo Moreau, Media Department
Office: +1 (704) 343-6361
E-mail: [email protected]

© 2019 Market Source Research. All Rights Reserved. For republishing permissions, please contact a partner network manager at [email protected].

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

FINRA®, BrokerCheck®, and CRD® are registered trademarks owned by Financial Industry Regulatory Authority, Inc.

ti?nf=NzQ5NDQxMiMyNzEwNTgwIzUwMDAzMTMyNg==